Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332100 | 1.00 | MEN1 (0.46) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL6327371 | 0.89 | MEN1 (0.42) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL6095179 | 0.85 | MEN1 (0.56) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL6335799 | 0.85 | MEN1 (0.51) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL7514139 | 0.84 | MEN1 (0.43) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL6326862 | 0.83 | MEN1 (0.52) | MEN1KMT2AALDH1A1KDM4EMAPK1 | |
| SCHEMBL6326790 | 0.83 | MEN1 (0.52) | MEN1KMT2AALDH1A1KDM4EMAPK1 | |
| SCHEMBL6316723 | 0.83 | MEN1 (0.53) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL6325216 | 0.82 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL6325518 | 0.82 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | US | disclosed |
| EP-1192156-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | DRD2, ADRA1D, KCND2 | MEN1 2418/4885KMT2A 2342/4885ALDH1A1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.